Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELUW) EBIT (2020 - 2025)

Historic EBIT for Celularity (CELUW) over the last 6 years, with Q3 2025 value amounting to -$12.9 million.

  • Celularity's EBIT fell 1191.12% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.5 million, marking a year-over-year decrease of 20787.29%. This contributed to the annual value of -$38.4 million for FY2024, which is 8005.17% up from last year.
  • Celularity's EBIT amounted to -$12.9 million in Q3 2025, which was down 1191.12% from -$15.9 million recorded in Q2 2025.
  • Celularity's 5-year EBIT high stood at $17.5 million for Q4 2022, and its period low was -$99.3 million during Q3 2023.
  • Moreover, its 5-year median value for EBIT was -$11.5 million (2024), whereas its average is -$21.3 million.
  • The largest annual percentage gain for Celularity's EBIT in the last 5 years was 32675.82% (2021), contrasted with its biggest fall of 2900729.81% (2021).
  • Celularity's EBIT (Quarter) stood at -$15.0 million in 2021, then surged by 216.95% to $17.5 million in 2022, then dropped by 23.85% to $13.3 million in 2023, then crashed by 169.7% to -$9.3 million in 2024, then plummeted by 39.01% to -$12.9 million in 2025.
  • Its EBIT was -$12.9 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$10.5 million in Q1 2025.